Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | HMOX1 | P09601 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL918222 | 1.00 | HTR2A (0.45) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL2368070 | 0.82 | IGF1R (0.43) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL1986354 | 0.82 | IGF1R (0.43) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL241160 | 0.82 | IGF1R (0.43) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL3839205 | 0.81 | IGF1R (0.40) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL1306565 | 0.80 | IGF1R (0.42) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL237732 | 0.80 | IGF1R (0.42) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL1305581 | 0.80 | IGF1R (0.42) | HTR2AIGF1RMEN1KMT2AHMOX1 | |
| SCHEMBL24164093 | 0.79 | LMNA (0.61) | LMNA | |
| SCHEMBL1318953 | 0.79 | LMNA (0.61) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-12540127-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2026-02-03 | — | — | US | disclosed |
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-10-23 | — | — | US | disclosed |
| EP-4613773-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-3731869-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| US-12258341-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-02 | — | — | US | disclosed |
| US-12168057-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-12-17 | — | — | US | disclosed |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-05-06 | — | — | US | disclosed |
| CN-101652361-A | 2-substituted-6-heterocyclic pyrimidone derivatives as tau protein kinase 1 inhibitors | MITSUBISHI TANABE PHARMA CORP | 2010-02-17 | — | — | CN | disclosed |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MITSUBISHI PHARMA CORPORATION (JP) | 2009-09-24 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| EP-2078717-A1 | 6-Pyrimidinyl-pyrimid-2-one derivative | sanofi-aventis (FR) | 2009-07-15 | — | — | EP | disclosed |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MITSUBISHI PHARMA CORPORATION (JP) | 2009-05-14 | — | — | US | disclosed |
| CN-101048397-A | 6-(pyridinyl)-4-pyrimidone derivates as tau protein kinase 1 inhibitors | MITSUBISHI PHARMA CORP (JP) | 2007-10-03 | — | — | CN | disclosed |
| CN-101035781-A | 2-morpholino-4-pyrimidone compound | MITSUBISHI PHARMA CORP (JP) | 2007-09-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250325673-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885IGF1R 540/4885MEN1 4055/4885 |
| US-12258341-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885IGF1R 540/4885MEN1 4055/4885 |
| US-20090124618-A1 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND | MAPT, PSEN1, PSEN2 | HTR2A 2123/4885IGF1R 2872/4885MEN1 1278/4885 |
| US-20250163042-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885IGF1R 540/4885MEN1 4055/4885 |
| US-20100113775-A1 | 2-SUBSTITUTED-6-HETEROCYCLIC PYRIMIDONE DERIVATIVES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, TTBK2 | HTR2A 3173/4885IGF1R 872/4885MEN1 3650/4885 |
| US-20250000985-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885IGF1R 540/4885MEN1 4055/4885 |
| US-20090239864-A1 | 6- (PYRIDINYL) -4-PYRIMIDONE DERIVATES AS TAU PROTEIN KINASE 1 INHIBITORS | MAPT, TTBK1, PSEN1 | HTR2A 2841/4885IGF1R 599/4885MEN1 3057/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885IGF1R 540/4885MEN1 4055/4885 |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | HTR2A 102/4885IGF1R 535/4885MEN1 1455/4885 |
| US-12168057-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | HTR2A 3621/4885IGF1R 540/4885MEN1 4055/4885 |
| US-12540127-B2 | CRBN ligands and uses thereof | CRBN, NR2C2, NR2E3 | HTR2A 1987/4885IGF1R 254/4885MEN1 3927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.